In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bio Angels and partner at Alloy Bio Consulting. We discuss why a life sciences-only angel group matters, how they evaluate opportunities, and the importance of strong teams, capital efficiency and a realistic path to exit.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/yaniv-sneor-5534131/" target="_blank">Yaniv Sneor</a>, Founder, Mid Atlantic Bio Angels<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/alexpederson/" target="_blank">Alex Pederson</a>, Investor, Mid Atlantic Bio Angels &amp; Partner, Alloy Bio ConsultingDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.